UFT and Its Metabolites Inhibit the Angiogenesis Induced by Murine Renal Cell Carcinoma, as Determined by a Dorsal Air Sac Assay in Mice

Kazuhiko Yonekura,1 Yuji Basaki, Lumi Chikahisa, Soko Okabe, Akihiro Hashimoto, Kazutaka Miyadera, Konstanty Wierzba, and Yuji Yamada

Cancer Research Laboratory, Hanno Research Center, Taiho Pharmaceutical Co., Ltd., 1-27 Misugidai, Hanno-city, Saitama, 357 Japan

ABSTRACT

UFT, an anticancer agent that is composed of tegafur (FT) and uracil at a molar ratio of 1:4, is widely used in clinical practice in Japan to treat cancer patients requiring a long-term chemotherapy, and it is associated with few side effects, if any. In this study, we have evaluated the inhibitory effect of UFT against RENCA cell-induced angiogenesis by a dorsal air sac assay. Marked angiogenesis is induced by implantation of a chamber containing RENCA cells into mice. In this model, UFT showed a strong angiogenesis-inhibitory effect, whereas 5-fluorouracil (5-FU) and doxifluridine were less effective. Additional experiments revealed FT to be effective component of UFT; uracil remained ineffective in the inhibition of angiogenesis. Moreover, we have found that γ-hydroxybutyric acid and γ-butyrolactone, the metabolites of FT, possess a potent angiogenesis inhibitory effect that is amplified when the compounds are administered by a continuous infusion. This may reflect a transition in blood concentration of each metabolite resulting from the administration of UFT. Similar results were also obtained with respect to 5-FU. It was suggested that UFT has a stronger angiogenesis-inhibitory effect than did other fluorinated pyrimidines, partly due to its pharmacokinetic properties characterized by maintaining of higher and long-lasting blood levels of 5-FU and partly due to the inhibitory effects derived from γ-hydroxybutyric acid and γ-butyrolactone, UFT-specific metabolites.

INTRODUCTION

Several fluorinated pyrimidines are widely used in the treatment of variety of cancers. UFT is one of frequently used drugs belonging to that class. We previously reported that UFT exhibited a significant life-prolonging effect that was associated with the decreased number of tumor vessels in the metastatic foci in a postoperative adjuvant model of RENCA (murine renal cell carcinoma) cell line (1). On the other hand, other fluorinated pyrimidines, e.g., 5-FU,2 a cytotoxic metabolite of FT, and 5′-DFUR, a derivative of 5-FU, neither exerted a significant prolongation of the life span nor affected the number of tumor vessels in treated animals. Furthermore, it was also noted that the drugs with a strong cytotoxicity such as CPT-11 and CDDP and a reference antiangiogenic agent, TNP-470, showed temporary antitumor and angiogenesis-inhibitory effects, but these did not result in significant prolongation of the life span. To achieve a life-prolonging effect, in many instances (2–4), it is necessary to administer a drug chronically, a method that is often limited by the toxic effects. Therefore, the balance between efficacy and toxicity is thought to be important to attain survival prolongation. As a matter of fact, only UFT among fluorinated pyrimidines shows, due to its unique biodisposition, a significant life-prolonging effect with simultaneous decreasing of the number of tumor vessels in our experimental model.

This finding seems to be of great importance because an inhibition of angiogenesis will prevent tumor mass enlargement and tumor cell spread into the circulation, thus blocking the formation of metastasis (5–7), which, in turn, will determine a survival of a cancer-invaded host organism.

The aims of this study were to: (a) provide a direct evidence of the angiogenesis inhibitory effect of UFT; (b) compare the efficacy of UFT with those of 5-FU and 5′-DFUR; and (c) identify active components derived from UFT, as shown in Fig. 1, that are responsible for that effect. For that purpose, a DAS assay was used with the induction of angiogenesis by the RENCA cells.

MATERIALS AND METHODS

Materials and Animals

UFT is a combination of FT and uracil, mixed at the molar ratio of 1:4 (2). FT was synthesized in our laboratory. Other drugs and reagents were purchased as follows: uracil, GBL, and 5-FU from Wako Pure Chemical Industries (Tokyo, Japan); GHB sodium salt from Sigma Chemical Co. (St. Louis, MO); and 5′-DFUR from Nippon Roche (Tokyo, Japan). Male BALB/cA mice (6 weeks old) were purchased from Charles River Japan (Tokyo, Japan).

UFT, FT, uracil and 5′-DFUR were suspended in 0.5%...
UFT Inhibits Tumor-induced Angiogenesis

Renca cells (10^6 cells) in 0.15 ml of PBS. The Renca resulting Millipore chamber was filled with the suspension of Oikawa triggered by Renca cells, according to a method described by UFT and other related compounds on the angiogenic response DAS Assay manufacturer.

and cultured in the exclusive medium provided by the manufacturer. FBS. MBMECs were purchased from Cell Applications, Inc., in RPMI 1640 (Life Technologies, Inc.) supplemented with 10% M. D. Anderson Cancer Center, Houston, TX). It was cultured provided by courtesy of Dr. I. J. Fidler (The University of Texas covered with Millipore filters of 0.45-
m pore size, and the same inner diameter as the Millipore rings were placed at the sites exposed to a direct contact with the chamber. The angiogenic response was assessed with a dissecting microscope photographs by determining the number of newly formed blood vessels of >3 mm in length within the area marked by the black ring. The extent of angiogenesis was scored as an index of 0, 1, 2, 3, 4, or 5, indicating zero, one, two, three, four, or five or more newly formed blood vessels, respectively. The blood vessels newly formed by an angiogenic factor(s) released from malignant tumor cells were morphologically distinct from the preexisting background vessels by the zigzagging characteristics (Fig. 2), as described previously (9–11).

The following experimental protocols were designed:

**Experiment 1.** Experiment 1 involved the evaluation of angiogenesis-inhibitory effects of UFT, 5-FU, and 5'-DFUR. Mice with the implanted chambers containing Renca cells were divided into six groups (n = 6). The positive control group received 0.5% HPMC by p.o. administration. The other three groups of animals were treated p.o. with UFT, at the dosage of 0.025, 0.05, and 0.1 mmol/kg/day. These dosages of UFT are expressed as the amount of FT contained in UFT preparation. Two more groups of animals were given either 5-FU i.v. (0.146 mmol/kg/day) or 5'-DFUR p.o. at a dose of 0.812 mmol/kg/day. The negative control group of animals, implanted with the chambers containing equal volume of PBS without cancer cells, was given a vehicle consisting of 0.5% HPMC. The doses of UFT 0.1 mmol/kg/day and 5'-DFUR 0.812 mmol/kg/day were selected for this experimental design because there had been often used in the treatment protocols of experimental cancers (12, 13). That of 5-FU of 0.146 mmol/kg/day is the maximum tolerated dose for five consecutive daily i.v. injections (14).

**Experiment 2.** Experiment 2 evaluated the angiogenesis-inhibitory effects of uracil and FT, the main components of UFT, and of 5-FU, GHB, and GBL, the metabolites of FT. The same procedure as that described for experiment 1 was used, and two control groups (positive controls, n = 8; and negative controls, n = 6) were used. UFT was p.o. administered at the dosage of 0.1 mmol/kg/day (as the amount of FT), and FT was given p.o. at the dosage of 0.1 and 0.5 mmol/kg/day. Uracil was given p.o., whereas 5-FU, GHB, and GBL were administered i.p. at equimolar dosages corresponding to 0.1 mmol/kg FT (n = 6).

**Experiment 3.** The inhibition of angiogenesis by 5-FU, GHB, and GBL, given either as a continuous infusion using osmotic pumps or by repeated i.p. administration (n = 6), was comparatively evaluated according to the above method. One group of animals was also treated with concomitant administration of 5-FU and GHB (n = 6). The osmotic pump was implanted in the lateral abdominal part of the mouse. The tested compounds were administered at the equimolar doses corresponding to 0.1 mmol/kg of UFT. Control animals were implanted with the osmotic pump containing saline only (n = 8).

(w/v) HPMC. 5-FU was dissolved in physiological saline solution for i.v. and i.p. administration and in 7% sodium bicarbonate solution for a continuous infusion study. Both GHB and GBL were dissolved in physiological saline solution. The osmotic pump manufactured by Alzet Inc. (Palo Alto, CA) was used for continuous drug infusion.

**Cells**

Renca cell line, a murine renal cell carcinoma, was provided by courtesy of Dr. I. J. Fidler (The University of Texas M. D. Anderson Cancer Center, Houston, TX). It was cultured in RPMI 1640 (Life Technologies, Inc.) supplemented with 10% FBS. MBMECs were purchased from Cell Applications, Inc., and cultured in the exclusive medium provided by the manufacturer.

**DAS Assay**

The DAS assay was used in mice to examine the effect of UFT and other related compounds on the angiogenic response triggered by Renca cells, according to a method described by Oikawa et al. (8). Briefly, both sides of a Millipore ring were covered with Millipore filters of 0.45-μm pore size, and the resulting Millipore chamber was filled with the suspension of Renca cells (10^6 cells) in 0.15 ml of PBS. The Renca cell-containing chamber was implanted into the preformed air sac in the dorsum of anesthetized (50 mg/kg pentobarbital, i.v.) male BALB/c A mouse. The animals were divided into treated groups on day 0, and the corresponding drugs were administered from day 0 to day 4. On day 5, the implanted chambers were removed from s.c. fascia of treated mice, and then black rings of the same inner diameter as the Millipore rings were placed at the sites exposed to a direct contact with the chamber. The angiogenic response was assessed with a dissecting microscope photographs by determining the number of newly formed blood vessels of >3 mm in length within the area marked by the black ring. The extent of angiogenesis was scored as an index of 0, 1, 2, 3, 4, or 5, indicating zero, one, two, three, four, or five or more newly formed blood vessels, respectively. The blood vessels newly formed by an angiogenic factor(s) released from malignant tumor cells were morphologically distinct from the preexisting background vessels by the zigzagging characteristics (Fig. 2), as described previously (9–11).

**Fig. 1** Main metabolic pathway of UFT, derived from the experiments in animal species and human patients following p.o. administration.

5-FU was dissolved in physiological saline solution for i.v. and i.p. administration and in 7% sodium bicarbonate solution for a continuous infusion study. Both GHB and GBL were dissolved in physiological saline solution. The osmotic pump manufactured by Alzet Inc. (Palo Alto, CA) was used for continuous drug infusion.

**Cells**

Renca cell line, a murine renal cell carcinoma, was provided by courtesy of Dr. I. J. Fidler (The University of Texas M. D. Anderson Cancer Center, Houston, TX). It was cultured in RPMI 1640 (Life Technologies, Inc.) supplemented with 10% FBS. MBMECs were purchased from Cell Applications, Inc., and cultured in the exclusive medium provided by the manufacturer.

**DAS Assay**

The DAS assay was used in mice to examine the effect of UFT and other related compounds on the angiogenic response triggered by Renca cells, according to a method described by Oikawa et al. (8). Briefly, both sides of a Millipore ring were covered with Millipore filters of 0.45-μm pore size, and the resulting Millipore chamber was filled with the suspension of Renca cells (10^6 cells) in 0.15 ml of PBS. The Renca cell-containing chamber was implanted into the preformed air sac in the dorsum of anesthetized (50 mg/kg pentobarbital, i.v.) male BALB/c A mouse. The animals were divided into treated groups on day 0, and the corresponding drugs were administered from day 0 to day 4. On day 5, the implanted chambers were removed from s.c. fascia of treated mice, and then black rings of the same inner diameter as the Millipore rings were placed at the sites exposed to a direct contact with the chamber. The angiogenic response was assessed with a dissecting microscope photographs by determining the number of newly formed blood vessels of >3 mm in length within the area marked by the black ring. The extent of angiogenesis was scored as an index of 0, 1, 2, 3, 4, or 5, indicating zero, one, two, three, four, or five or more newly formed blood vessels, respectively. The blood vessels newly formed by an angiogenic factor(s) released from malignant tumor cells were morphologically distinct from the preexisting background vessels by the zigzagging characteristics (Fig. 2), as described previously (9–11).

The following experimental protocols were designed:

**Experiment 1.** Experiment 1 involved the evaluation of angiogenesis-inhibitory effects of UFT, 5-FU, and 5'-DFUR. Mice with the implanted chambers containing Renca cells were divided into six groups (n = 6). The positive control group received 0.5% HPMC by p.o. administration. The other three groups of animals were treated p.o. with UFT, at the dosage levels of 0.025, 0.05, and 0.1 mmol/kg/day. These dosages of UFT are expressed as the amount of FT contained in UFT preparation. Two more groups of animals were given either 5-FU i.v. (0.146 mmol/kg/day) or 5'-DFUR p.o. at a dose of 0.812 mmol/kg/day. The negative control group of animals, implanted with the chambers containing equal volume of PBS without cancer cells, was given a vehicle consisting of 0.5% HPMC. The doses of UFT 0.1 mmol/kg/day and 5'-DFUR 0.812 mmol/kg/day were selected for this experimental design because there had been often used in the treatment protocols of experimental cancers (12, 13). That of 5-FU of 0.146 mmol/kg/ day is the maximum tolerated dose for five consecutive daily i.v. injections (14).

**Experiment 2.** Experiment 2 evaluated the angiogenesis-inhibitory effects of uracil and FT, the main components of UFT, and of 5-FU, GHB, and GBL, the metabolites of FT. The same procedure as that described for experiment 1 was used, and two control groups (positive controls, n = 8; and negative controls, n = 6) were used. UFT was p.o. administered at the dosage of 0.1 mmol/kg/day (as the amount of FT), and FT was given p.o. at the dosage of 0.1 and 0.5 mmol/kg/day. Uracil was given p.o., whereas 5-FU, GHB, and GBL were administered i.p. at equimolar dosages corresponding to 0.1 mmol/kg FT (n = 6).

**Experiment 3.** The inhibition of angiogenesis by 5-FU, GHB, and GBL, given either as a continuous infusion using osmotic pumps or by repeated i.p. administration (n = 6), was comparatively evaluated according to the above method. One group of animals was also treated with concomitant administration of 5-FU and GHB (n = 6). The osmotic pump was implanted in the lateral abdominal part of the mouse. The tested compounds were administered at the equimolar doses corresponding to 0.1 mmol/kg of UFT. Control animals were implanted with the osmotic pump containing saline only (n = 8).
**Experiment 4.** The dose-dependent inhibition of angiogenesis by GHB was also evaluated according to the above methods. GHB was administered by a continuous infusion at the dose of 0.1 mmol/kg/day, corresponding to 0.1 mmol/kg of UFT, and at two additional doses of 0.02 and 0.5 mmol/kg/day, being 5 times decreased or increased in respect to the middle dose, respectively.

**In Vitro Cytotoxicity**

The *in vitro* cytotoxicity of the tested compounds against RENCA cells or MBMECs was determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay after a 72-h incubation (15).

**Statistical Analysis**

Paired comparison of the angiogenesis indices of the control group and those of the drug groups was conducted by means of two-tailed Wilcoxon’s exact test. Differences were considered to be statistically significant if \( P \) was \( \leq 0.05 \).

**RESULTS**

**Inhibition of Angiogenesis by Fluorinated Pyrimidines.**

The implantation of the chambers containing only PBS (negative control) was associated with a minimal angiogenesis. The mean angiogenesis index value accounted for only 0.67, indicating that the experimental manipulation and subsequent healing process did not induce a significant angiogenic response. Occasionally, only a single microvessel was presented in some of control animals (Table 1). On the other hand, RENCA cells separated by a semipermeable filter (positive control) triggered the neovascularization process, which was characterized by the angiogenesis index of 4.17. As shown in Table 1 and Fig. 2, UFT suppressed a RENCA cell-induced angiogenesis in a dose-dependent manner. Particularly, the pronounced effect of UFT was observed at the dose level of 0.1 mmol/kg, which is commonly used for the evaluation of the antitumor activity of UFT. The other two drugs tested, namely, 5-FU and 5'-DFUR, showed a minimal and nonsignificant angiogenesis-inhibitory effect. These results indicate that UFT is the strongest inhibitor of angiogenesis among clinically used fluorinated pyrimidines.

*Fig. 2* The illustration of the angiogenic response induced by RENCA cells in BALB/cA mice and its inhibition by the administration of UFT and 5'-DFUR for 5 consecutive days. The vehicle-treated group was implanted with chambers containing PBS only (A), and the control group was implanted with chambers containing RENCA cells (B). Arrowheads, newly formed vessels, with characteristic zigzagging lines. The number of this type of vessels is reduced by the treatment with 5'-DFUR (0.812 mmol/kg/day; C) and almost completely abolished by the treatment with UFT (0.1 mmol/kg/day; D).
**Table 1** Inhibitory effect of UFT, 5-FU, and 5'-DFUR on the angiogenic response induced by RENCA cells in BALB/c mice.

<table>
<thead>
<tr>
<th>Group</th>
<th>Route</th>
<th>Schedule</th>
<th>Dose (mmol/kg/day)</th>
<th>Individual index</th>
<th>Angiogenesis index</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vehicle</td>
<td>p.o.</td>
<td>qd x 5</td>
<td></td>
<td>0 1 1 1 1 0</td>
<td>0.67 ± 0.21</td>
</tr>
<tr>
<td>Control</td>
<td>p.o.</td>
<td>qd x 5</td>
<td>0.025</td>
<td>5 3 5 5 5 2</td>
<td>4.17 ± 0.54</td>
</tr>
<tr>
<td>UFT</td>
<td>p.o.</td>
<td>qd x 5</td>
<td>0.050</td>
<td>2 0 5 5 5 0</td>
<td>2.83 ± 1.01</td>
</tr>
<tr>
<td>UFT</td>
<td>p.o.</td>
<td>qd x 5</td>
<td>0.100</td>
<td>2 0 5 0 5 2</td>
<td>2.33 ± 1.02</td>
</tr>
<tr>
<td>5-FU</td>
<td>i.v.</td>
<td>qd x 5</td>
<td>0.146</td>
<td>1 2 0 5 5 2</td>
<td>2.50 ± 1.05</td>
</tr>
<tr>
<td>5'-DFUR</td>
<td>p.o.</td>
<td>qd x 5</td>
<td>0.812</td>
<td>0 4 5 2 2 1</td>
<td>2.33 ± 0.76</td>
</tr>
</tbody>
</table>

* Mice were implanted with a chamber containing RENCA cells (1 × 10⁶/cells) or PBS in a vehicle group (n = 6). The angiogenic response was assessed on day 5 by determining the number of newly formed blood vessels of ≥3 mm in length within the area contacted with a chamber and graded into six ranks as follows: angiogenesis index of 0, 1, 2, 3, 4, or 5, indicating formed blood vessels, zero, one, two, three, four, or five or more respectively.

† Not significant.

‡ P < 0.05 versus controls by two-tailed Wilcoxon exact test.

Inhibition of Angiogenesis by the Component of UFT and Its Metabolites. Because only UFT inhibited the angiogenesis induced by RENCA cells, it was essential to identify a component involved in this activity. As shown in Fig. 1, UFT is a mixture of FT and uracil at a molar ratio of 1:4 (16). Under in vivo conditions, FT is oxidized and then 5-FU and GHB are released; the latter is in equilibrium with GBL as the result of chemical interconversion (17, 18). The dose-dependent inhibitory effect was observed after administration of FT, the main active component of UFT. The other component, uracil, was completely inactive (Fig. 3). Among metabolic species of UFT, significant inhibition of angiogenesis was observed only after administration of GHB and GBL; however, no significant inhibitory tendency was observed in the case of 5-FU (Fig. 3).

Angiogenesis-inhibitory Effects of the Metabolites of UFT Given as a Continuous Infusion. The above-mentioned metabolism of FT takes place in the liver and is mediated by the cytochrome P-450; therefore, the indicated metabolites, namely, 5-FU, GHB, and GBL, appear in the blood in patterns similar to those of compounds that are administered in the form of a sustained-release formulation (17–19). In addition, uracil, contained in UFT, prevents further enzymatic degradation of the released 5-FU (16). To mimic the sustained release pharmacokinetic profile of 5-FU, GHB, and GBL, the main metabolites of UFT, we infused the mentioned compounds by a micro-osmotic pump and compared their inhibitory effects with those observed after i.p. administration. The results shown in Fig. 4 indicate that the drug delivery in the form of a continuous infusion was associated with the stronger inhibition of the angiogenesis by any of the administered compounds.

Angiogenesis-inhibitory Effect of GHB Administered by Continuous Infusion. GHB inhibited the angiogenesis induced by RENCA cells in a dose-dependent manner (Fig. 5). When GHB was administered at the maximum dose of 0.5 mmol/kg/day, the angiogenic activity in treated animals returned to the control levels.

Cytotoxicity Study of 5-FU, GHB, and GBL. The cytotoxic effects of 5-FU, GHB, and GBL against RENCA cells and MBMECs were evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenytetrazolium bromide assay, and the results are shown in Fig. 6. The calculated IC₅₀ₐₕₕ of 5-FU were determined to be 0.83 and 49 µM for RENCA and MBMEC cells, respectively. On the other hand, both GHB and GBL appeared to be not cytotoxic against both cell lines, even at a concentration of 10 mm.

DISCUSSION

We have previously reported a significant life-prolonging effect of UFT in animals with a metastatic form of RENCA cancer (postoperative adjuvant model). This effect was associated with the decrease of the number of microvessels in the
metastatic nodules formed in the lung (1). Kurebayashi et al. (20) also reported that UFT significantly inhibited micrometastasis using a postoperative adjuvant model of MKL-4 cells, derived from MCF-7 cell line by the transfection with a fgf-4 gene, which encodes a potent angiogenic factor. These results suggested that UFT may affect the angiogenesis in the growing tumors and, consequently, prompted us to examine directly whether UFT can inhibit tumor cell-induced angiogenesis.

Among various widely accepted methods used to evaluate the inhibition of angiogenesis (21–23), the DAS assay seemed to be the most suitable one in this study. This method has an advantage because the direct observation of angiogenesis induced by tumor cells is possible and is applicable to the compounds, which show an activity after being metabolized. Two compounds under recent evaluation, namely, UFT and 5'-DFUR, are activated in vivo to more potent and pharmacologically active metabolites (17, 24, 25). Therefore, it is thought to be more beneficial than the chick embryo chorioallantoic membrane assay or gelatin sponge method (21–23).

The results of the evaluation of angiogenesis-inhibitory effects of the fluorinated pyrimidines by DAS assay have shown that UFT is the only compound among them that exerts a strong inhibition of the angiogenesis induced by cancer cells. Significant suppression of angiogenesis was also observed after treat-
ment with FT, a component of UFT preparation (16). Uracil, the other component of UFT, was without any effect. This led us to the assumption that the angiogenesis-inhibitory effect of UFT may originate from 5-FU, GHB, and GBL, the metabolites of FT (17, 18). Surprisingly, it appeared to be true that predominant metabolites of UFT exerted the inhibitory effect, especially those lacking cytotoxicity. The angiogenesis-inhibitory effect of UFT was reconstituted in vivo after concomitant i.p. administration of 5-FU and GHB, where at least an additive effect was seen, suggesting that both metabolites of UFT contribute to the inhibition of the neovascularization process (Fig. 4). Furthermore, we have found that the method of drug delivery essentially contributes to the inhibition of the angiogenesis. The inhibitory effects of GHB, GBL, and 5-FU were more pronounced when they were administered as a continuous infusion, providing a suitable pharmacokinetic profile that is observed after UFT administration. These results suggest that a stronger inhibition of angiogenesis by UFT is attainable by the sustained in vivo distribution of GHB/GBL. It is reported in the clinical study that the half-life of GHB is relatively short after a single administration (26, 27). However, after administration of UFT, the concentrations of GHB as well as that of 5-FU in the blood are maintained for a relatively long time due to a gradual generation from FT by cytochrome P-450 present in the liver (17–19). As shown in this study, such a property is beneficial to the attainment of angiogenesis inhibition.

In the DAS assay, RENCA cells are closed in the filter chamber of 0.45-μm pore size, and the angiogenesis is thought to be induced by angiogenic factors that are produced by RENCA cells. The process of angiogenesis can be roughly separated into the following three steps: growth, migration/invasion, and tube formation by vascular endothelial cells (5–7). Because GHB has no cytotoxicity against both RENCA and vascular endothelial cells, it is thought to inhibit the processes other than cell growth. Vasil’eva et al. (28) have reported about the effect of GHB on microvessels density as an early phenomenon seen in the celloidin-induced inflammation model in rats. There was no direct evidence of the inhibition of microvascular formation; rather, the results indicated the presence of unspecified pharmacological effects on the blood supply to the inflammation site. In this study, we have provided the evidence that GHB, a noncytotoxic agent, effectively inhibits tumor-induced neovascularization.

On the other hand, a strong angiogenesis-inhibitory effect of 5-FU was observed after administration of a relatively low dose by a continuous infusion, and the i.p. injections were virtually ineffective. Because the in vitro cytotoxic effect of 5-FU on MBMECs is weak (Fig. 6) and only a weak angiogenesis-inhibitory effect was attainable by i.v. bolus administration (Table 1), one may consider that 5-FU also inhibits angiogenesis by the mechanism different from that of cell growth inhibition. Both UFT and 5′-DFUR are metabolized to 5-FU, however, after administration of 5′-DFUR the serum levels of 5-FU only temporarily become high (24, 25, 29). On the other hand, the serum levels of 5-FU following UFT administration are sustained for a relatively longer time than those derived from 5′-DFUR, and the peak levels are not high enough to induce a severe toxic effects (24, 25, 29). Pharmacokinetic profile of 5-FU after administration of UFT is more similar to that of low dose 5-FU given by a continuous infusion. This pharmacokinetic pattern of 5-FU is assumed to play an important role in the inhibition of angiogenesis. We have previously reported that an appropriate dosage of FT has a selective effect on immunocompetent cells and enhances cellular immunity or immune response to the tumor (30, 31). The progressive growth of tumors depending on angiogenesis is often associated with an inflammatory process that can be regulated by several chemokines and/or cytokines involved in the tumor angiogenesis (32–34). These properties of FT may contribute to the angiogenesis-inhibitory effect of UFT by keeping the antiangiogenic balance in the host.

Angiogenesis is closely associated with tumor mass expansion, and it enhances the tumor’s metastasizing ability (5–7). The studies of angiogenesis-inhibitory effects of antitumor agents are considered to have significant implications in terms of life prolongation and the improvement of quality of life of patients suffering of cancer. Recently used antitumor agents have a serious limitation in clinical usage due to their strong cytotoxicity and short-lasting therapeutic effects that usually not lead to life-prolonging effects, owing to their severe toxicity (2–4). The results of this study have indicated that UFT inhibits tumor-induced angiogenesis and suggested that this effect may contribute to the life prolonging or to antitemetastatic effect of UFT in postoperative adjuvant therapy. Also, newly discovered properties of the metabolites of UFT may serve as leading structures for the development of noncytotoxic agents inhibiting the angiogenesis induced by a growing tumor mass. We are now studying in detail the mechanism of angiogenesis inhibition and the population of cancers responding to UFT.

REFERENCES


UFT and Its Metabolites Inhibit the Angiogenesis Induced by Murine Renal Cell Carcinoma, as Determined by a Dorsal Air Sac Assay in Mice

Kazuhiko Yonekura, Yuji Basaki, Lumi Chikahisa, et al.


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/5/8/2185

Cited articles
This article cites 30 articles, 12 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/5/8/2185.full.html#ref-list-1

Citing articles
This article has been cited by 18 HighWire-hosted articles. Access the articles at:
/content/5/8/2185.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.